DAPTA - CAS 106362-34-9
Catalog number:
106362-34-9
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C35H56N10O15
Molecular Weight:
856.89
COA:
Inquire
Targets:
CCR
Description:
CCR5 antagonist
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
CCR5 antagonist
Appearance:
White lyophilised solid
Synonyms:
(2S)-N-[(2S)-1-[[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]-2-[[(2S,3R)-2-[[(2S,3R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2R)-2-aminopropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amin
Solubility:
Soluble to 1 mg/ml in water
Storage:
Desiccate at -20°C
MSDS:
Inquire
Quality Standard:
In-house
Quantity:
Milligrams-Grams
Boiling Point:
1514.3°Cat760mmHg
InChIKey:
CC(C(C(=O)N)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CC(=O)N)NC(=O)C(C(C)O)NC(=O)C(C(C)O)NC(=O)C(C(C)O)NC(=O)C(CO)NC(=O)C(C)N)O
InChI:
1/C35H56N10O15/c1-13(36)29(54)41-22(12-46)32(57)43-26(16(4)49)34(59)45-27(17(5)50)35(60)44-25(15(3)48)33(58)40-21(11-23(37)52)30(55)39-20(10-18-6-8-19(51)9-7-18)31(56)42-24(14(2)47)28(38)53/h6-9,13-17,20-22,24-27,46-51H,10-12,36H2,1-5H3,(H2,37,52)(H2,38,5
Canonical SMILES:
OC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)[C@H](O)C)Cc1ccc(cc1)O)CC(=O)N)[C@H](O)C)[C@H](O)C)[C@H](O)C)NC(=O)[C@H](N)C
1.Age-specific influences of chronic administration of the fatty acid amide hydrolase inhibitor URB597 on cardiovascular parameters and organ hypertrophy in DOCA-salt hypertensive rats.
Toczek M1, Baranowska-Kuczko M1, Grzęda E1, Pędzińska-Betiuk A1, Weresa J1, Malinowska B2. Pharmacol Rep. 2016 Apr;68(2):363-9. doi: 10.1016/j.pharep.2015.10.004. Epub 2015 Oct 24.
BACKGROUND: The endocannabinoid system has been suggested to be up-regulated in hypertension. Fatty acid amide hydrolase (FAAH) is the main hydrolytic enzyme for the encocannabinoid anandamide. The aim of our study was to examine the age-specific influence of the chronic administration of the FAAH inhibitor URB597 on blood pressure (BP), heart rate (HR) and cardiac and renal hypertrophy in hypertensive rats during two critical periods for the development of hypertension.
2.Enhanced function of inhibitory presynaptic cannabinoid CB1 receptors on sympathetic nerves of DOCA-salt hypertensive rats.
Toczek M1, Schlicker E2, Grzęda E1, Malinowska B3. Life Sci. 2015 Oct 1;138:78-85. doi: 10.1016/j.lfs.2015.03.022. Epub 2015 Apr 25.
AIMS: This study was performed to examine whether hypertension affects the sympathetic transmission to resistance vessels of pithed rats via inhibitory presynaptic cannabinoid CB1 receptors and whether endocannabinoids are involved in this response.
3.Parabrachial lesions in rats disrupt sodium appetite induced by furosemide but not by calcium deprivation.
Grigson PS1, Colechio EM2, Power ML3, Schulkin J4, Norgren R5. Physiol Behav. 2015 Mar 1;140:172-9. doi: 10.1016/j.physbeh.2014.11.070. Epub 2014 Dec 22.
An appetite for CaCl2 and NaCl occurs in young rats after they are fed a diet lacking Ca or Na, respectively. Bilateral lesions of the parabrachial nuclei (PBN) disrupt normal taste aversion learning and essentially eliminate the expression of sodium appetite. Here we tested whether similar lesions of the PBN would disrupt the calcium-deprivation-induced appetite for CaCl2 or NaCl. Controls and rats with PBN lesions failed to exhibit a calcium-deprivation-induced appetite for CaCl2. Nevertheless, both groups did exhibit a significant calcium-deprivation-induced appetite for 0.5M NaCl. Thus, while damage to the second central gustatory relay in the PBN disrupts the appetite for 0.5M NaCl induced by furosemide, deoxycorticosterone acetate, and polyethylene glycol, the sodium appetite induced by dietary CaCl2 depletion remains intact.
4.Protective role of cannabinoid CB1 receptors and vascular effects of chronic administration of FAAH inhibitor URB597 in DOCA-salt hypertensive rats.
Baranowska-Kuczko M1, Kozłowska H2, Kloza M2, Karpińska O2, Toczek M2, Harasim E3, Kasacka I4, Malinowska B2. Life Sci. 2016 Apr 15;151:288-99. doi: 10.1016/j.lfs.2016.03.014. Epub 2016 Mar 9.
AIMS: This study examined whether the fall in blood pressure (BP) induced by the chronic inhibition of fatty acid amide hydrolase (FAAH) by URB597 in deoxycorticosterone acetate (DOCA-salt) hypertensive rats correlates with endocannabinoid-mediated vascular changes.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related CCR Products


CAS 1173022-16-6 RS 102895 hydrochloride

RS 102895 hydrochloride
(CAS: 1173022-16-6)

CCR2b antagonist

CAS 624733-88-6 MK-0812

MK-0812
(CAS: 624733-88-6)

Potent and selective CCR2 antagonist with low nM affinity for CCR2 on human monocytes

CAS 1341224-83-6 PF-4136309

PF-4136309
(CAS: 1341224-83-6)

Potent, selective, and orally bioavailable CCR2 antagonist

Vercirnon
(CAS: 698394-73-9)

Highly potent antagonist of CCR9

CAS 1780259-94-0 ZK756326 (dihydrochloride)

ZK756326 (dihydrochloride)
(CAS: 1780259-94-0)

ZK756326 is a selective and nonpeptide chemokine receptor agonist for the CC chemokine receptor CCR8 (IC50= 1.8 muM).

K-11777
(CAS: 233277-99-1)

K-11777 is a potent, irreversible cysteine protease inhibitor. Besides, K11777 is not only a substrate but also a mechanism-based inhibitor of CYP3A4.

CAS 106362-34-9 DAPTA

DAPTA
(CAS: 106362-34-9)

CCR5 antagonist

CP-481715
(CAS: 212790-31-3)

CP-481715 is a potent and selective CCR1 antagonist with >100-fold selective for CCR1 as compared with a panel of G-protein-coupled receptors including related ...

CAS 887401-93-6 INCB 3284 dimesylate

INCB 3284 dimesylate
(CAS: 887401-93-6)

Potent, selective and orally bioavailable CCR2 antagonist with IC50 of 3.7 nM.

CAS 497223-25-3 Cenicriviroc

Cenicriviroc
(CAS: 497223-25-3)

Cenicriviroc is an inhibitor of CCR2 and CCR5 receptors, allowing it to function as an entry inhibitor which prevents the virus from entering into a human cell ...

CAS 300816-15-3 RS 504393

RS 504393
(CAS: 300816-15-3)

Highly selective CCR2 antagonist

JNJ 27141491
(CAS: 871313-59-6)

Potent and selective human CCR2 antagonist

CAS 217645-70-0 BX 471

BX 471
(CAS: 217645-70-0)

Selective CCR1 antagonist

CAS 445479-97-0 BMS CCR2 22

BMS CCR2 22
(CAS: 445479-97-0)

High affinity, potent CCR2 antagonist

CAS 887401-92-5 INCB 3284

INCB 3284
(CAS: 887401-92-5)

Potent, selective and orally bioavailable CCR2 antagonist with IC50 of 3.7 nM

TAK-220
(CAS: 333994-00-6)

An orally bioavailable small-molecule CCR5 antagonist

CAS 58816-69-6 SB 297006

SB 297006
(CAS: 58816-69-6)

Potent and selective CCR3 antagonist

CAS 874911-96-3 ZK 756326

ZK 756326
(CAS: 874911-96-3)

Selective, non-peptide CCR8 agonist

CH0076989
(CAS: 54371-52-9)

CH0076989 is a small molecule agonist for CCR3. It activates a number of signalling pathways including chemotaxis and receptor internalisation.

Teijin compound 1
(CAS: 1313730-14-1)

Potent CCR2b antagonist

Chemical Structure

CAS 106362-34-9 DAPTA

Quick Inquiry

Verification code

Featured Items